Background/Purpose
Results of the previously reported randomized–controlled WEGENT trial demonstrated that, at 28 months, methotrexate (MTX) is as effective as azathioprine (AZA) for maintaining remission of granulomatosis with polyangiitis (GPA, Wegener’s) or severe microscopic polyangiitis (MPA) (NEJM 2008;359:2790–803). The long-term outcomes of patients included in the WEGENT trial were analyzed in this study.
Methods
Long-term outcomes were ascertained for 126 patients enrolled in the WEGENT trial between 1999 and 2004. Data on survival, relapse, immunosuppressant use, cancer, infection and cardiovascular morbidity were collected. All patients were analyzed according to their randomization group. Demographic, clinical and laboratory parameters at trial entry were evaluated as potential prognostic factors for death or relapse in multivariate models.
Results
Median follow-up was 11.8 years. The 10-year overall survival rate was 74.8% [95% CI 64.5–86.9] for the AZA arm and 79.9% [95% CI 70.3–90.7] for the MTX arm, with no between-arm survival difference (HR MTX vs AZA = 0.79 [95% CI 0.37–1.70]; P=0.55). No long-term between-arm differences were observed for adverse events, severe adverse events, infections, cancer, relapses and severe relapses. The 10-year survival rate without relapse was 26.3% [95% CI 17.3–40.1] in the AZA arm and 35.1% [95% CI 24.9-49.4] in the MTX arm, with no significant between-arm difference (HR MTX vs AZA = 0.78 [95% CI 0.51–1.20]; P=0.26). The 10-year survival rate without severe side effects was also comparable for the two groups (HR MTX vs AZA = 1.02 [95% CI 0.64–1.63]; P=0.93), as was survival without relapse and severe side effects (HR MTX vs AZA = 1.04 [95% CI 0.66–1.63]; P=0.87). Taking into account only the 97 GPA patients, no between-arm differences were observed for these survival parameters. Survival without relapse was shorter for GPA than MPA patients (HR 2.16 [95% CI 1.22–3.83]; P=0.009). Multivariate analyses retained the glucocorticoid dose at the end of the scheduled 12-month maintenance-drug regimen (HR 1.18 [95% CI 1.09–1.29]; P<0.001), glucocorticoid duration (HR 1.01 [95%CI 1.00–1.02]; P<0.04), and PR3-ANCA–positivity (HR 3.68 [95% CI 2.07–6.55]; P<0.001) as being significantly prognostic of long-term relapses. Each additional month or mg of glucocorticoid at the end of the maintenance regimen increased the probability of relapse or death by 1% or 15%, respectively.
Conclusion
This long-term analysis confirmed that AZA and MTX are comparable options for maintaining GPA or MPA remission. It showed that the overall survival is good, even though relapses and adverse events remain matters of concern. Further studies are needed to reduce the long-term relapse rate of ANCA-associated vasculitides.
Disclosure:
X. Puéchal,
None;
C. Pagnoux,
None;
E. Perrodeau,
None;
M. Hamidou,
None;
J. J. Boffa,
None;
X. Kyndt,
None;
F. Lifermann,
None;
T. Papo,
None;
D. Merrien,
None;
A. Smail,
None;
P. Delaval,
None;
C. Hanrotel-Saliou,
None;
B. Imbert,
None;
C. Khouatra,
None;
M. Lambert,
None;
C. Leské,
None;
K. H. Ly,
None;
E. Pertuiset,
None;
P. Roblot,
None;
M. Ruivard,
None;
J. F. Subra,
None;
J. F. Viallard,
None;
B. Terrier,
None;
P. Cohen,
None;
L. Mouthon,
None;
P. Ravaud,
None;
L. Guillevin for the French Vasculitis Study Group,
None.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/granulomatosis-with-polyangiitis-or-microscopic-polyangiitis-long-term-outcomes-of-the-prospective-wegent-trial-comparing-azathioprine-vs-methotrexate-for-remission-maintenance-in-126-patients/